Alveolar macrophages from EVALI patients and e-cigarette users: a story of shifting phenotype

Respir Res. 2023 Jun 17;24(1):162. doi: 10.1186/s12931-023-02455-w.

Abstract

Exposure to e-cigarette vapors alters important biologic processes including phagocytosis, lipid metabolism, and cytokine activity in the airways and alveolar spaces. Little is known about the biologic mechanisms underpinning the conversion to e-cigarette, or vaping, product use-associated lung injury (EVALI) from normal e-cigarette use in otherwise healthy individuals. We compared cell populations and inflammatory immune populations from bronchoalveolar lavage fluid in individuals with EVALI to e-cigarette users without respiratory disease and healthy controls and found that e-cigarette users with EVALI demonstrate a neutrophilic inflammation with alveolar macrophages skewed towards inflammatory (M1) phenotype and cytokine profile. Comparatively, e-cigarette users without EVALI demonstrate lower inflammatory cytokine production and express features associated with a reparative (M2) phenotype. These data indicate macrophage-specific changes are occurring in e-cigarette users who develop EVALI.

Keywords: Alveolar macrophages (AM); Bronchoalveolar lavage (BAL); E-cigarette; Or vaping; Product use-associated lung injury (EVALI).

MeSH terms

  • Biological Products*
  • Cytokines
  • Electronic Nicotine Delivery Systems*
  • Humans
  • Lung Injury*
  • Macrophages, Alveolar
  • Phenotype

Substances

  • Biological Products
  • Cytokines